Jonathan Pollack
@jonathanpollack.bsky.social
Photographer, jack of all trades | #IgANephropathy patient | Amateur researcher | #STL
I am both too sick and too well by the numbers to participate in any #IgAN clinical trials. Somebody design an investigative trial around my numbers.
November 19, 2025 at 10:35 PM
I am both too sick and too well by the numbers to participate in any #IgAN clinical trials. Somebody design an investigative trial around my numbers.
If you take away one thing and one thing only from this, let it be the pronunciation guide for saying atacicept.
November 18, 2025 at 2:10 PM
If you take away one thing and one thing only from this, let it be the pronunciation guide for saying atacicept.
November 17, 2025 at 3:35 PM
Reposted by Jonathan Pollack
A phase 2 trial shows rilparencel improves annual eGFR slope, which suggests the cell therapy may preserve kidney function in patients with diabetic nephropathy.
www.renalandurologynews.com/reports/chro... #KidneyWk #KidneyCare
www.renalandurologynews.com/reports/chro... #KidneyWk #KidneyCare
Rilparencel Autologous Cell Therapy May Slow Progression of Advanced CKD With Diabetes - Renal and Urology News
Rilparencel, a percutaneous minimally invasive injectable product prepared from patients’ own kidney cells, is being developed to treat those with stage 3b or 4 CKD and either type 1 or type 2 diabete...
www.renalandurologynews.com
November 14, 2025 at 4:11 PM
A phase 2 trial shows rilparencel improves annual eGFR slope, which suggests the cell therapy may preserve kidney function in patients with diabetic nephropathy.
www.renalandurologynews.com/reports/chro... #KidneyWk #KidneyCare
www.renalandurologynews.com/reports/chro... #KidneyWk #KidneyCare
Seems to me at least that aggressive proteinuria control is the way to go for better outcomes - evidence that @kdigo.org guidelines are spot-on. #IgAN #IgANephropathy #NephSky
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
More info: academic.oup.com/ndt/article/...
@ndt-era.bsky.social, @hjanders.bsky.social
CKD progression, kidney failure, and mortality among US patients with IgA nephropathy
ABSTRACTBackground and Hypothesis. We assessed disease progression among patients with immunoglobulin A nephropathy (IgAN) and characterized factors associ
academic.oup.com
November 14, 2025 at 3:20 PM
Seems to me at least that aggressive proteinuria control is the way to go for better outcomes - evidence that @kdigo.org guidelines are spot-on. #IgAN #IgANephropathy #NephSky
November 13, 2025 at 6:52 PM
It's definintely not a one-size fits all approach, and regardless all CKD diets need updating to reflect the latest research about protein and potassium restriction. #NephSky
For decades, the “renal diet” has been a standard part of chronic kidney disease (CKD) management.
But as the science of nutrition and nephrology has evolved, an important question has emerged: does the traditional renal diet still make sense?
www.renalandurologynews.com/features/ren...
But as the science of nutrition and nephrology has evolved, an important question has emerged: does the traditional renal diet still make sense?
www.renalandurologynews.com/features/ren...
Why a Traditional “Renal Diet” Falls Short
Renal diets for chronic kidney disease (CKD) require a dietitian’s assessment, personalization, and support for behavior change.
www.renalandurologynews.com
November 13, 2025 at 6:51 PM
It's definintely not a one-size fits all approach, and regardless all CKD diets need updating to reflect the latest research about protein and potassium restriction. #NephSky
I wish caffeine actually worked on (in?) me. I hear it can keep you awake.
November 12, 2025 at 2:10 PM
I wish caffeine actually worked on (in?) me. I hear it can keep you awake.
November 12, 2025 at 12:18 AM
I believe my retirement job will be professional rat tickler.
🐀Male and female rats like to be tickled differently - males prefer rougher play.
🤣How do we know? Rats produce ultrasonic giggles that can be monitored with a bat detector.
🧪Why is this relevant? To improve lab animal welfare.
Ah, to tickle rats for a living...♥️
f1000research.com/articles/14-...
🤣How do we know? Rats produce ultrasonic giggles that can be monitored with a bat detector.
🧪Why is this relevant? To improve lab animal welfare.
Ah, to tickle rats for a living...♥️
f1000research.com/articles/14-...
November 11, 2025 at 4:23 PM
I believe my retirement job will be professional rat tickler.
How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Mezagitamab Stablized eGFR 18 Months After Treatment in IgAN
Phase 1b IgAN data: mezagitamab (TAK‑079) stabilized eGFR, reduced proteinuria and serum Gd-IgA1, no serious AEs through Week 96; Phase 3 trials enrolling.
www.takeda.com
November 11, 2025 at 3:25 PM
How'd I miss this one? Phase 1b results for mezagitamab, an anti-CD38 monoclonal antibody. (All meds should come with a pronunciation guide.) #NephSky #KidneyWk #IgAN #IgANephropathy
Getting my cystatin C checked today!
Among more than 800 000 CKD-PC participants, discordance between cystatin C and creatinine eGFR values was associated with increased risk of death, cardiovascular events, and kidney failure.
ja.ma/47A5Gdd
ja.ma/47A5Gdd
November 11, 2025 at 12:58 PM
Getting my cystatin C checked today!
Reposted by Jonathan Pollack
Serum and urine metabolic fingerprints enable diagnosis and prognosis for IgA nephropathy #MaterTodayBio #MassSpec www.sciencedirect.com/science/arti...
Serum and urine metabolic fingerprints enable diagnosis and prognosis for IgA nephropathy
IgA nephropathy (IgAN), the most common primary glomerulonephritis worldwide, displays a pronounced geographical variation and progresses to end-stage…
www.sciencedirect.com
November 10, 2025 at 8:21 PM
Serum and urine metabolic fingerprints enable diagnosis and prognosis for IgA nephropathy #MaterTodayBio #MassSpec www.sciencedirect.com/science/arti...
Shockingly, nobody is discussing pork left over after harvesting for xenotransplantation. Imagine getting a new kidney and then stocking your freezer as a bonus. #KidneyWk
November 9, 2025 at 1:40 PM
Shockingly, nobody is discussing pork left over after harvesting for xenotransplantation. Imagine getting a new kidney and then stocking your freezer as a bonus. #KidneyWk
November 9, 2025 at 3:51 AM
Reposted by Jonathan Pollack
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. nej.md/493Xtza
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
November 8, 2025 at 4:35 PM
In an interim analysis, sibeprenlimab, a humanized IgG2 monoclonal antibody that inhibits the proliferation-inducing ligand APRIL (a key driver of IgA nephropathy), reduced proteinuria as compared with placebo. nej.md/493Xtza
@asnkidney.bsky.social | #KidneyWk
@asnkidney.bsky.social | #KidneyWk
Vera has submitted a BLA for atacicept based on ORIGIN 3 data presented at #KidneyWk. #IgAN #NephSky
Vera Therapeutics Submits Biologics License Application to U.S. FDA through Accelerated Approval Program for Atacicept for the Treatment of Adults with IgA Nephropathy | Vera Therapeutics
Atacicept received FDA Breakthrough Therapy Designation for the treatment of IgAN ORIGIN Phase 3 trial met its primary endpoint at the prespecified interim analysis of proteinuria reduction with 46% r...
ir.veratx.com
November 8, 2025 at 12:02 AM
Reposted by Jonathan Pollack
#KidneyWk: Patients with #IgAN who receive #Ravulizumab have lower markers of #KidneyInjury and complement activation, according to results from the phase 2 #SANCTUARY trial.
Read here: https://bit.ly/4oriYOW
#KidneyWeek #RareDisease #Nephrology #MedSky
Read here: https://bit.ly/4oriYOW
#KidneyWeek #RareDisease #Nephrology #MedSky
Ravulizumab May Reduce Complement Activation in IgAN
Findings from the SANCTUARY study suggest that ravulizumab may reduce kidney injury and complement activation in patients with IgAN.
bit.ly
November 7, 2025 at 6:25 PM
#KidneyWk: Patients with #IgAN who receive #Ravulizumab have lower markers of #KidneyInjury and complement activation, according to results from the phase 2 #SANCTUARY trial.
Read here: https://bit.ly/4oriYOW
#KidneyWeek #RareDisease #Nephrology #MedSky
Read here: https://bit.ly/4oriYOW
#KidneyWeek #RareDisease #Nephrology #MedSky
Just watched the @hcplivenews.bsky.social Kidney Compass recap of ORIGIN 3 and I want to hear @brendonneuen.bsky.social saying, "Renaissance," in a loop. #KidneyWk
November 7, 2025 at 1:29 AM
Just watched the @hcplivenews.bsky.social Kidney Compass recap of ORIGIN 3 and I want to hear @brendonneuen.bsky.social saying, "Renaissance," in a loop. #KidneyWk
Reposted by Jonathan Pollack
Dual Role of #Factor H–Related Protein 1 in #IgA #Nephropathy Kidney Injury
#VisualAbstract by Jade Teakell, MD
https://www.kireports.org/article/S2468-0249(25)00622-9/fulltext
#VisualAbstract by Jade Teakell, MD
https://www.kireports.org/article/S2468-0249(25)00622-9/fulltext
November 7, 2025 at 12:00 AM
Dual Role of #Factor H–Related Protein 1 in #IgA #Nephropathy Kidney Injury
#VisualAbstract by Jade Teakell, MD
https://www.kireports.org/article/S2468-0249(25)00622-9/fulltext
#VisualAbstract by Jade Teakell, MD
https://www.kireports.org/article/S2468-0249(25)00622-9/fulltext